Days
Hours
Minutes
Seconds

Fortrea and Omico Collaborate to Connect Genomically Profiled Patients With Biomarker-Led CRO Oncology Trials in Australia

COMPANY PROFILE
  • Fortrea (Nasdaq: FTRE), a leading global CRO, and Omico, Australia’s leading precision oncology screening and trial matching organization, have announced a collaboration to accelerate biomarker-led oncology drug development in Australia — combining Fortrea’s oncology clinical trial execution capabilities with Omico’s PrOSPeCT program, Australia’s largest cancer genomics initiative, which has more than 23,000 consented patients in its clinico-genomic databases and referrals from over 1,600 clinicians nationwide.
  • The collaboration will give Fortrea’s biopharma clients access to patient population insights, genomic profiling data, trial-matching capabilities, real-world oncology evidence, and patient referral pathways through Omico — improving investigator site selection, accelerating biomarker-matched patient identification, and expanding access to precision oncology studies across Australia’s established early and late-phase clinical research infrastructure.

Fortrea (Nasdaq: FTRE), a leading global CRO, and Omico, Australia’s leading precision oncology screening and trial matching organization, announced on October 22, 2026, from Durham, North Carolina and Sydney, Australia, a collaboration designed to accelerate precision oncology research by connecting cancer patients with biomarker-matched clinical trials. The initiative brings together Fortrea’s oncology clinical trial expertise with Omico’s flagship Precision Oncology Screening Platform Enabling Clinical Trials — PrOSPeCT — the largest cancer genomics initiative in Australia, giving Fortrea’s biopharma clients a direct pathway to genomically characterized patient populations and trial-matching infrastructure that would otherwise require years to establish independently.

Through the collaboration, Omico will support Fortrea’s oncology drug development clients by providing access to patient population insights drawn from its clinico-genomic databases — covering more than 23,000 consented patients — alongside genomic profiling data, trial-matching capabilities, real-world oncology evidence, and patient referral pathways spanning a nationwide network of more than 1,600 clinicians and Australia’s leading cancer research institutes. For CRO sponsors planning biomarker-driven oncology studies, this infrastructure translates directly into improved feasibility assessment, more efficient investigator site selection, and the ability to identify eligible patient subpopulations at the protocol planning stage rather than after study activation — compressing one of the most consistently underestimated sources of oncology trial delay.

Australia occupies a strategically significant position for precision oncology CRO programs. The country’s established clinical research infrastructure, ICH-aligned regulatory framework, and competitive tax credit environment make it an efficient geography for both early-phase first-in-human studies and later-phase biomarker-driven programs — and Omico’s national network integrates directly with the hospital and cancer center infrastructure through which the majority of oncology trial patients are recruited. Fortrea’s engagement with Omico is designed to embed that Australian patient access directly into its global oncology CRO delivery model, with both organizations operating under a joint framework that spans study planning, site selection, patient recruitment, and real-world evidence generation.

Fortrea’s oncology platform is underpinned by more than 50 oncology physicians on staff and thousands of operational professionals working across approximately 100 countries. The Omico collaboration is announced three days after Fortrea completed the acquisition of Worldwide Clinical Trials’ Early Phase Services division — which added a 200-bed clinical pharmacology unit in San Antonio and a 60,000 sq ft GLP bioanalytical laboratory in Austin to its global early-phase CRO network — indicating a period of concentrated strategic investment across multiple nodes of the oncology and early-phase development value chain simultaneously.

“Our collaboration with Omico is about seeking to reach the right patient for the right study as quickly as possible. Modern oncology development demands ever-greater precision to match specific cancers with the therapies most likely to benefit patients, and to do so as quickly as possible. Our work with Omico accelerates our ability to identify the right patients for biomarker-driven studies in Australia and help advance precision medicine for people with cancer.”

Oren Cohen, M.D., Chief Medical Officer, Fortrea

Sign up to the free weekly newsletter for all the latest news, resources and podcasts in contract manufacturing.  Register here